

[AccessPharmacy >](#)

McGraw-Hill's NAPLEX® Review Guide, 2e, 2014 > Vaccines and Immunizations

S. Scott Sutton

TABLE 69-1

Vaccine Indications

Vaccine	Indication	Target Population
DTaP	Prevention of diphtheria, tetanus, and pertussis	Children <7 y of age
Td	Booster immunization against tetanus and diphtheria as well as tetanus prophylaxis in wound management	Adolescents and adults >7 y of age
Tdap	Booster immunization against tetanus, diphtheria, and pertussis	Adolescents and adults ≥11 y of age
DT	Prevention of diphtheria and tetanus	Children <7 y of age who are allergic to the pertussis vaccine
Hep A	Prevention of hepatitis A infection	Children >12 mo of age
		Adults at high risk for Hep A infection
Hep B	Prevention of hepatitis B infection	All infants beginning at birth
		Unvaccinated children and adolescents
		Adults at high risk for Hep B infection
Hib	Prevention of invasive bacterial disease caused by <i>Haemophilus influenzae</i> type b	Children <5 y of age Adults with sickle cell disease, asplenia, leukemia, or HIV infection
HPV-4	Prevention of cervical cancer, precancerous or dysplastic lesions, and genital warts caused by the human papillomavirus types 6, 11, 16, 18	Females aged 9-26 y Males 9-26 y ^a
HPV-2	Prevention of cervical cancer, cervical intraepithelial neoplasia, and adenocarcinoma in situ caused by HPV types 16 and 18	Females aged 10-26 y
IPV	Prevention of poliomyelitis caused by poliovirus types 1,2,3	All children
MCV, MPSV	Prevention of invasive meningococcal disease caused by <i>N. meningitidis</i> serogroups A, C, Y, W135	Adolescents 11-12 y of age Adults at high risk for meningococcal disease
MMR	Prevention of measles, mumps, rubella, and congenital rubella syndrome	Children >12 mo of age
PCV	Prevention of invasive pneumococcal disease caused by <i>S. pneumoniae</i>	Adults ≥65 y of age Children <2 y of age High risk adults (cochlear implant, asplenia, cerebrospinal fluid leaks, immunocompromising condition, or immunosuppressive therapy) ≥19-64 y of age ^b
PPSV	Prevention of invasive pneumococcal disease caused by <i>S. pneumoniae</i>	Adults ≥65 y of age Aged 2-64 y with chronic heart disease (excluding hypertension), chronic lung disease, diabetes mellitus, cerebrospinal fluid leaks, cochlear implant, alcoholism, chronic liver disease, asplenia, immunocompromising condition or therapy, or those who smoke

Vaccine	Indication	Target Population
RV	Prevention of gastroenteritis caused by rotavirus	Infants aged 6 wk to 8 mo
Varicella	Prevention of varicella caused by varicella-zoster	Children >12 mo
Zoster	Prevention of shingles and reducing the pain associated with shingles caused by herpes zoster	Adults over the age of 60 y ^c

^aHPV-4 vaccine used in males to prevent genital warts.

^bPCV vaccine is FDA approved for children <5 years and adults 50 years and older.

^cZoster vaccine is FDA approved for adults aged 50 years and older; however, ACIP still only recommends it for those 60 years and older.